First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

July 1, 2025

Study Completion Date

July 31, 2025

Conditions
Hepatocellular CarcinomaLiver Cancer
Interventions
DRUG

MTL-CEBPA

Intravenous administration

DRUG

Sorafenib 200mg

Sorafenib tablets

Trial Locations (11)

Unknown

National University Hospital, Singapore

National Taiwan University Hospital, Taipei

University Hospitals Birmingham NHS Foundation Trust, Birmingham

Cambridge University Hospitals NHS Trust, Cambridge

The Beatson West of Scotland Cancer Centre, Glasgow

Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool

Guy's and St. Thomas' NHS Foundation Trust, London

Imperial College Healthcare NHS Trust, London

The Royal Free London NHS Foundation Trust, London

University College London Hospitals NHS Foundation Trust, London

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle

All Listed Sponsors
lead

Mina Alpha Limited

INDUSTRY